This article was downloaded by: [Michigan State University] On: 13 February 2015, At: 15:12 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides and Nucleotides

Publication details, including instructions for authors and subscription information: <u>http://www.tandfonline.com/loi/lncn19</u>

Synthetic Nucleoside and Nucleotides. XXXIV. Photoaffinity Labeling of HIV Reverse Transcriptase: Synthesis and Utilization of 2',3'-Dideoxy Uridylate Analogs Bearing Aryl(trifluor0methyl)-Diazirine Moiety

Toyofumi Yamaguchi ^a & Mineo Saneyoshi ^a ^a Department of Biological Sciences , The Nishi-Tokyo University , 2525 Yatsuzawa, Uenohara-machi, Kitatsuru-gun, Yamanashi, 409-01, Japan Published online: 21 Aug 2006.

To cite this article: Toyofumi Yamaguchi & Mineo Saneyoshi (1996) Synthetic Nucleoside and Nucleotides. XXXIV. Photoaffinity Labeling of HIV Reverse Transcriptase: Synthesis and Utilization of 2',3'-Dideoxy Uridylate Analogs Bearing Aryl(trifluor0methyl)-Diazirine Moiety, Nucleosides and Nucleotides, 15:1-3, 607-618

To link to this article: <u>http://dx.doi.org/10.1080/07328319608002409</u>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms

& Conditions of access and use can be found at <u>http://www.tandfonline.com/page/</u> terms-and-conditions

SYNTHETIC NUCLEOSIDE AND NUCLEOTIDES. XXXIV. PHOTOAFFINITY LABELING OF HIV REVERSE TRANSCRIPTASE: SYNTHESIS AND UTILIZATION OF 2',3'-DIDEOXY URIDYLATE ANALOGS BEARING ARYL(TRIFLUOROMETHYL)-DIAZIRINE MOIETY^{†,1}

Toyofumi Yamaguchi * and Mineo Saneyoshi

Department of Biological Sciences, The Nishi-Tokyo University, 2525 Yatsuzawa, Uenohara-machi, Kitatsuru-gun, Yamanashi 409-01, Japan

ABSTRACT: In order to develop a photoaffinity labeling reagent for HIV-1 reverse transcriptase, a 2',3'-dideoxyUTP analog bearing a photo-reactive group at the 5-position of the uracil ring, 2',3'-dideoxy-E-5-[4-[3-(trifluoromethyl)-3H-diazirin-3-yl]styryl]-UTP, was designed and synthesized. This photo-reactive analog could preferentially bind to the 66 kDa subunit of the p66/p51 heterodimeric HIV-1 reverse transcriptase under irradiation by near-ultraviolet light (365 nm).

The nucleoside analogs such as 3'-azido-3'-deoxythymidine (AZT), 2',3'-dideoxycytidine (DDC), 2',3'-dideoxyinosine (DDI) and 2',3'-didehydro-3'-deoxythymidine (D4T) inhibit the replication of human immunodeficiency viruses type 1 (HIV-1) and have been used clinically in the treatment of acquired immunodeficiency syndrome (AIDS). These nucleosides are known to be phosphorylated and exert their activity by inhibiting HIV reverse transcriptase ²⁻⁶. Thus, HIV reverse transcriptase has been proved to be one of the important target molecules for developing anti-HIV agents. The 5'-triphosphates of the 2',3'-dideoxythymidine analogs including AZT 5'-triphosphate (AZT-TP), 2',3'-dideoxythymidine 5'-triphosphate (ddTTP) and D4T 5'-triphosphate have been demonstrated to be potent inhibitors of HIV-1 reverse transcriptase ⁷⁻⁹. Therefore, it is important to investigate the three-dimensional interactions between these 2',3'-dideoxythymidine 5'-triphosphate analogs and the amino acid residues at the active site of the HIV reverse transcriptase molecule in comparison with eukaryotic DNA polymerases. We have attempted to

[†] This paper is dedicated to Dr. Yoshihisa Mizuno on occasion of his 75th birthday.

Copyright © 1996 by Marcel Dekker, Inc.



FIG. 1. Reaction scheme for the synthesis of 2',3'-dideoxy-E-5-[4-[3-(trifluoromethyl)-3H-diazirin-3-yl]styryl]uridine (4) and the structures of phosphorylated derivatives of 4, AZT-TP, ddTTP and StddUTP.

find a photoaffinity labeling reagent for the active site(s) of HIV-1 reverse transcriptase and examine the labeling of this enzyme. From the results of crystallographic analysis 10,11 and our labeling experiment of HIV-1 reverse transcriptase, structural information about the catalytic site(s) of HIV-1 reverse transcriptase will be obtained, and these may be useful in designing a selective inhibitor for the enzyme. In a previous study, we demonstrated that the inhibitory effect of 2',3'-dideoxy-*E*-5-styryluridine 5'-triphosphate (StddUTP), which bears steric and hydrophobic styryl groups at the 5-position of the uracil ring on the HIV-1 reverse transcriptase, was as potent as ddTTP ¹². Using this information, we have designed 2',3'-dideoxy-*E*-5-[4-[3-(trifluoromethyl)-3*H*-diazirin-3-yl]styryl]UTP (TDSddUTP) (7) and its radiolabeled form **8** which have a photoreactive aryl(trifluoromethyl)diazirine group as the carbene precursor. This diazirine group is stable and easily handled for labeling studies compared to the aryl azido functional group 13,14 . The present paper deals with the synthesis and application of TDSddUTPs (7 and 8).

MATERIALS AND METHODS

UV spectra were recorded on a Beckman DU70 recording spectrophotometer. ¹H-NMR spectra were obtained on a JEOL GSX400 NMR spectrometer with tetramethylsilane as an internal standard. Mass spectra were measured on a JEOL JMS-01 SG-2 spectrometer. High-performance liquid chromatography (HPLC) was performed using a Shimadzu LC-9A apparatus, with a flow rate of 0.80 ml/min. *Method A*-A YMC Pack ODS A-302 (YMC Co., Ltd.) reversed phase column (4.5 mm x 15 cm) was used. The solvent was aqueous CH₃CN containing 0.05 M Et₃NHOAc (pH 7.0). *Method B*-A TSK-GEL DEAE-2SW (Tohso Co., Ltd.) ion exchange column (4.5 mm x 25 cm)was used, with 0.21 M potassium phosphate buffer (pH 6.95) containing 20% (v/v) CH₃CN as the solvent. The analyses were performed at 45 °C.

[³H]dTTP and [γ-³²P]ATP were purchased from Amersham. Yeast nucleoside 5'-diphosphate kinase was purchased from Sigma. Recombinant HIV-1 reverse transcriptase, which showed 51 and 66 kDa bands in approximately equimolar proportions on SDS-PAGE, was purchased from Seikagaku Kogyo.

2',3'-Dideoxy-E-5-[4-[3-(trifluoromethyl)-3H-diazirin-3-yl]styryl]uridine (4). A solution of mercuric acetate (7.0 g, 22 mmol) in water (40 ml) was added to a mixture of 2',3'-dideoxyuridine (1) (4.5 g, 21.2 mmol) dissolved in water (30 ml), and the mixture was stirred for 8 h at 50 °C. After the addition of NaCl (3 g, 52 mmol), the mixture was stirred for 1 h at room temperature. The precipitates were collected by filtration and washed with 0.15 M aqueous sodium chloride (200 ml), ethanol (30 ml) and finally with ether (30 ml). Crude 5-chloromercuri-2',3'-dideoxyuridine (2) (5.5 g, 13 mmol) was obtained as a white solid and used in the next step without further purification. The well dried 2 (1.77 g, 4.0 mmol) was suspended in methanol (25 ml), and then 3-(4-ethenylphenyl)-3-trifluoromethyl-3H-diazirine (3)¹⁵ (1.02 g, 4.8 mmol) and a methanolic solution of 0.1 M lithium tetrachloropalladate (42 ml) were added. After being refluxed for 5 h, the reaction mixture was filtered and the filtrate was evaporated. The residue was chromatographed on a column of silica gel (100 g) with dichloromethane–ethylacetate–methanol (20:5:1, v/v). Between the two major products, the early-eluting fractions were collected and evaporated to dryness. The residue was chromatographed again under the same conditions. The fractions containing nucleoside **4** were combined and the solvent was removed under reduced pressure to give **4** as yellowish solid. 0.17 g (0.4 mmol, 10%). HPLC retention time: 3.99 min (*Method A*, 60% CH₃CN–0.05M Et₃NHOAc). UV (H₂O) λ max 316 nm (ϵ 22200), (50 mM NaOH) λ max 321 nm (ϵ 23700). ¹H-NMR (DMSO- d_6) δ : 1.90 (m, 2 H, H-3'), 2.05 (m, 1 H, H-2'), 2.30 (m, 1 H, H-2'), 3.60 (m, 1 H, H-5'), 3.80 (m, 1 H, H-5'), 4.07 (m, 1 H, H-4'), 5.26 (dd, 1 H, 5'-OH), 5.97 (dd, 1 H, H-1'), 6.98 (d, 1 H, olefinic-H, J = 15 Hz), 7.22 (d, 2 H, aromatic-H), 7.41 (d, 1 H, olefinic-H, J = 15 Hz), 7.57 (d, 1 H, aromatic-H), 8.44 (s, 1 H, H-6). HR-MS m/z: 422.1236 and 394.1173 (M⁺–N₂). Calcd. for C₁₉H₁₇F₃N₄O₄: 422.1202 and 394.1140.

2',3'-Dideoxy-*E*-5-[4-[3-(trifluoromethyl)-3*H*-diazirin-3-yl]styryl]uridine 5'-monophosphate (5). Phosphoryl chloride (0.2 ml, 2.14 mmol) was added dropwise to a solution of the nucleoside 4 (85 mg, 0.21 mmol) in triethyl phosphate (2 ml) at -10 °C, and the solution was stored for 1 day at 4 °C. The mixture was poured into 0.1 M sodium bicarbonate (100 ml) with stirring and extracted with chloroform (10 ml x 2). The aqueous layer was applied to a column of DEAE-cellulose (2.5 cm x 20 cm, bicarbonate form) pre-equilibrated with water. Elution was performed with a linear gradient (2,000 ml) of 0 to 0.5 M triethylammonium bicarbonate (pH 7.8). The main peak of UV absorption, eluted at 0.30 to 0.35 M, was collected and evaporated to dryness. In order to remove residual triethylammonium bicarbonate, the resulting residue was co-evaporated with water. The 5'-monophosphate 5 (3,400 OD₃₁₅ units, 0.16 mmol) was isolated as the triethylammonium salt in 73% yield.

2',3'-Dideoxy-E-5-[4-[3-(trifluoromethyl)-3H-diazirin-3-yl]styryl]-

uridine 5'-triphosphate (7) and 5'-diphosphate (6). A mixture of 5'-monophosphate 5 (388 OD_{315} units, 0.018 mmol) and 1,1'-carbonyldiimidazole (14.4 mg, 0.088 mmol) in dimethylformamide (DMF) (1 ml) was stirred for 2.5 h at room temperature, and methanol (2.7 μ l, 0.067 mmol) was added to the mixture. After stirring for 30 min, a solution of tri-*n*-butylammonium pyrophosphate (0.6 M, 0.3 ml) in DMF was added and the mixture was stirred for 24 h at room temperature. The solvent was removed under reduced pressure, and the residual syrup was dissolved in water (50 ml). Active carbon (Norit A) (0.4 g) was added to the solution and the mixture was stirred for 15 min. The mixture was filtered and the active carbon was washed well with water. Elution of the nucleotides from the active carbon was performed with 1.5 M ammonium

hydroxide containing 50% (v/v) ethanol. The eluate was evaporated to dryness, and the residue was dissolved in water (50 ml). The solution was applied to a column of DEAE-cellulose (2.5 cm x 10 cm, bicarbonate form) pre-equilibrated with water. The column was washed with 0.1 M triethylammonium bicarbonate (pH 7.8), and the elution was performed with a linear gradient (600 ml) of 0.10 to 0.70 M triethylammonium bicarbonate (pH 7.8). The main peak of UV absorption, which eluted at 0.5 to 0.6 M, was collected and evaporated to dryness. After co-evaporation with water, the 5'-triphosphate (7) (158 OD_{315} units) was isolated as the triethylammonium salt with a 40% yield. About 10 OD_{315} units of the product was further purified by HPLC (*Method A*, 27% (v/v) CH₃CN–0.05 MEt₃NHOAc). Finally, 7 was analyzed by HPLC (*Method A*, 30% (v/v) CH₃CN–0.05 MEt₃NHOAc) and the purity of 7 assessed by measuring UV absorption at 315 nm was confirmed to be greater than 95%.

In a similar fashion, the 5'-diphosphate (6) was synthesized, using the reaction of tri*n*-butylammonium phosphate instead of tri-*n*-butylammonium pyrophosphate. HPLC retention times of 5'-di- and 5'-triphosphates (6 and 7) using *Method B* were 11.4 and 14.3 min respectively. 5'-Dephosphorylation of the di- and triphosphate (6 and 7) was carried out with bacterial alkaline phosphatase (Nippon Gene, *E. coli* C75) using 20 nmol of 6 or 7 and 1 unit of the enzyme in 0.1 M Tris–HCl (pH 8.0), 1 mM MgCl₂ in a total volume of 250 μ l. Incubation was performed for 2 h at 37 °C. The digested products were confirmed by comparison with the nucleoside (4) using HPLC (*Method A*, 60% (v/v) CH₃CN–0.05 M Et₃NHOAc).

[γ -³ ²**P**]2',3'-Dideoxy-*E*-5-[4-[3-(trifluoromethyl)-3*H*-diazirin-3-yl]styryl]UTP (8). Nucleoside 5'-diphosphate kinase (2.5 units) in 0.1 M Tris-HCl (pH 7.5) (12 µl) was added to an aqueous solution (18 µl) of 2',3'-dideoxy-*E*-5-[4-[3-(trifluoromethyl)-3*H*-diazirin-3-yl]styryl]UDP (6) (0.5 OD₃₁₅ units, 23 nmol) and [γ -³²P]ATP (3.0 MBq, 0.12 nmol), and the mixture was incubated for 1 h at 37 °C. The product was chromatographed on a DEAE-cellulose column (0.8 cm x 9 cm) with a linear gradient (100 ml) of 0 to 1.0 M triethylammonium bicarbonate (pH 7.8). The main peak of radioactivity was collected and evaporated to dryness. The final product (2.0 MBq) was stored at -20 °C in the dark.

Assay of HIV-1 reverse transcriptase activity. The reaction mixture (25 μ l) comprised 50 mM Tris-HCl (pH 8.3), 1 mM dithiothreitol, 100 μ g/ml bovine serum albumin, 50 mM KCl, 0.5 mM MnCl₂, 60 μ g/ml poly (A)-oligo(dT)₁₂₋₁₈ (2:1, w/w), 50

 μ M [³H]dTTP (12 Bq/pmol), various concentrations of inhibitors and 5 ng HIV-1 reverse transcriptase. Incubation was carried out for 20 min at 37 °C. The reaction mixtures were then chilled and transferred to DE81 ion-exchange papers (Whatman). The papers were washed with 5% Na₂HPO₄ (six times) and dried. The radioactivity of the polynucleotides retained on the paper was then measured. When kinetic analysis was performed, the concentrations of [³H]dTTP and the inhibitors were varied.

Photoaffinity labeling of HIV-1 reverse transcriptase. The reaction mixture (7.5 μ l) comprised 50 mM Tris-HCl (pH 8.3), 1 mM dithiothreitol, 50 mM KCl, 80 μ g/ml poly(A), 20 μ g/ml oligo(dT)₁₂₋₁₈, 5.6 kBq [γ -³²P]TDSddUTP (**8**), 40 ng HIV-1 reverse transcriptase and 0 or 0.5 mM MnCl₂. When the effect of dTTP was examined, 10 μ M dTTP was also included. Incubation was carried out for 5 min at 25 °C in the dark. After chilling the reaction mixture, it was irradiated with a 100W black-light lamp (UVP, Inc. BA100AF) at a distance of 8 cm for 15 min on an ice bath. The mixture was mixed with 7.5 μ l of the solution consisting of 0.1 M Tris-HCl (pH 6.8), 4% SDS, 20% (v/v) glycerol, 50 mM dithiothreitol and 0.02% bromophenol blue, and then heat-denatured for 5 min at 95 °C. The samples were then subjected to SDS-PAGE. After detection of the protein bands by staining with Coomassie brilliant blue, the gel was dried and exposed to X-ray film (Konica) with an intensifying screen for 2 to 6 h at -70 °C. The radioactivity associated with the 66 kDa polypeptide was determined by Cerenkov counting after excising the radioactive band from gel.

SDS-PAGE. SDS-PAGE was carried out according to the method of Laemmli ¹⁶, using 10% separation gel and 5% condensation gel. Protein bands were detected by staining with Coomassie brilliant blue.

RESULTS

Synthesis. For the synthesis of an uracil nucleoside bearing a styryl group at the 5position of the uracil ring, a method using an organopalladium intermediate was utilized^{17,18}. In the present study, 2',3'-dideoxyuridine was converted to its 5-mercurated derivative **2** by treatment with mercuric acetate and sodium chloride ¹⁹, and then 3-(4ethenylphenyl)-3-trifluoromethyl-3*H*-diazirine (**3**)¹⁵ was reacted with **2** in the presence of lithium tetrachloropalladate in methanol. After purification by silica gel column chromatography, the desired nucleoside **4** was obtained as a yellowish powder. Proton NMR spectra of this nucleoside **4** showed that the coupling constant (*J*) between the vinylic protons of the styryl moiety at the 5-position was 15 Hz, indicating that the styryl substituent was "trans" ¹⁷. Compound **4** was then converted to the corresponding 5'-monophosphate **5** by phosphorylation with phosphoryl chloride in triethyl phosphate ²⁰, and further phosphorylated to the 5'-diphosphate **6** and 5'-triphosphate **7** by the phosphoroimidazolidate method ²¹. The isotope-labeled compound **8** was prepared from the corresponding 5'-diphosphate **7** and [γ -³²P]ATP, catalyzed by nucleoside diphosphate kinase essentially as described by Glynn and Chappell ²².

Inhibitory effect of 2',3'-dideoxy-E-5-[4-[3-(trifluoromethyl)-3Hdiazirin-3-yl]styryl]UTP (TDSddUTP, 7) on HIV-1 reverse transcriptase in the dark. We measured the inhibitory effect of TDSddUTP (7) on HIV-1 reverse transcriptase with poly(A)-oligo(dT) as the template-primer comparing it with ddTTP and StddUTP. As shown in Figure 2A, HIV-1 reverse transcriptase activity was inhibited strongly by these three compounds, and 50% inhibition of TDSddUTP (7) was observed at about 0.5 μ M in the presence of 50 μ M dTTP. From double reciprocal plots, the mode of inhibition of HIV-1 reverse transcriptase by TDSddUTP (7) was shown to be competitive with respect to dTTP (Figure 2B). The Ki value of TDSddUTP (7) for HIV-1 reverse transcriptase was determined as 0.075 μ M (Table 1), and was about 180 times smaller than the Km of dTTP (14 μ M).

Photoaffinity labeling of HIV-1 reverse transcriptase. The radioactive analog **8** was treated with HIV-1 reverse transcriptase and irradiated with near UV light (365 nm) at 0 °C. The radiolabeled product was analyzed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and detected by autoradiography. The effects of Mn²⁺ and dTTP on the photoaffinity labeling reaction were examined using poly(A)-oligo(dT) as the template-primer. As shown in Figure 3, radioactivity was detected at Mr = 66,000 in the absence of Mn²⁺, and generation of the radiolabeled polypeptide was inhibited by addition of 10 μ M dTTP. Under the condition of photolabeling, approximately 3% of [γ -³²P]TDS-ddUTP (**8**) was converted into the covalent complex which was detected at Mr = 66,000. No loss of HIV-1 reverse transcriptase activity was detected during the above irradiation procedure in the absence of TDSddUTP (**7**).

DISCUSSION

For developing a photoaffinity labeling reagent for HIV reverse transcriptase and other DNA polymerases which are sensitive to 2',3'-dideoxynucleoside 5'-triphosphates, we



FIG. 2. A. Inhibitory effects of TDSddUTP (7), StddUTP and ddTTP on HIV-1 reverse transcriptase in the dark. Inhibitory effects of these compounds were measured with poly(A)-oligo(dT) as the template-primer in the presence of 50 μ M [³H]dTTP. **B**. Lineweaver-Burk plot for the inhibition of HIV-1 reverse transcriptase by TDSddUTP (7) in the dark. Poly(A)-oligo(dT) was used as the template-primer.

	<i>K</i> i (µM)	Mode of inhibition
Inhibition by	· · · · · · · · · · · · · · · · · · ·	
TDSddUTP (7)	0.075	competitive c
StddUTP	0.050	competitive ^c
ddTTP	0.040	competitive c
Km for [³ H]dTTP	14	1

TABLE 1. Kinetic constants of HIV-1 reverse transcriptase for TDSddUTP (7), StddUTP and ddTTP. Poly(A)-oligo(dT) was used as the template-primer.

^c Competitive with respect to dTTP.



FIG. 3. Photoaddition of [γ-³²P]TDSddUTP (8) to HIV-1 reverse transcriptase. A mixture was incubated for 5 min at 25 °C in the dark using poly(A)-oligo(dT) as the template-primer, and subjected to near UV irradiation. The radiolabeled product was analyzed by SDS-PAGE, and detected by autoradiography as described in "MATERIALS AND METHODS". Lane 1, with 0.5 mM MnCl₂;
2, without MnCl₂; 3, without MnCl₂, but with 10 µM dTTP; 4, without MnCl₂, and no photolysis control.

designed and synthesized a 2',3'-dideoxyUTP analog (7 and 8) bearing an aryl(trifluoromethyl)diazirine system which was proved to be suitable for photo-reactive crosslinking^{13,14}. In this study, 2',3'-dideoxyuridine (1) was converted to its mercurated derivative 2, and then reacted with a styrene analog 3 in the presence of lithium tetrachloropalladate in methanol. The desired nucleotide 7 and its [γ -³²P] labeled form (8) were synthesized by chemical and enzymatic phosphorylation of the nucleoside 4. As a photoaffinity labeling reagent for HIV-1 reverse transcriptase, tritium-labeled BI-RJ-70, an arylazido photoaffinity analog of Nevirapine, has been synthesized and successfully used for labeling HIV-1 reverse transcriptase. However, this compound binds to a noncatalytic modulatory site of the enzyme ^{23,24}. As labeling reagents which could bind to the dNTP binding site of DNA polymerases by a photo-reaction, the nucleotide analogs bearing an arylazido group, 8-azido-dATP for *E. coli* DNA polymerase I ²⁵ and *E*-5-(4-azidostyryl)araUTP for cherry salmon DNA polymerase α ²⁶, were reported.

In a previous paper, we reported that 2',3'-dideoxy-*E*-5-styrylUTP showed a remarkable inhibitory effect on HIV-1 reverse transcriptase in a competitive fashion with respect to the substrate dTTP 12 . In this study, we demonstrated that TDSddUTP (7) also

inhibited the enzyme activity, as well as ddTTP or StddUTP, with the same mode of inhibition. These results suggest that replacement of the methyl group of ddTTP with a styryl or 4-[3-(trifluoromethyl)-3*H*-diazirin-3-yl]styryl group at the 5-position does not particularly affect the inhibitory effect on the reaction of HIV-1 reverse transcriptase.

Photoaffinity labeling experiments using a radioactive analog 8 showed that radiolabeled product was detected as the band at 66 kDa (Figure 3). This result is consistent with the fact that of the 51 and 66 kDa subunits of HIV-1 reverse transcriptase, only the 66 kDa subunit catalyses the polymerase reaction. However, when the labeling experiment was performed in the presence of Mn²⁺, the radioactive band at 66 kDa was not detected. Mn^{2+} is one of the common divalent cations used in the assay of DNA polymerases, providing the Mn-dNTP chelates. Incorporation of the dNMP moiety and release of pyrophosphate occurs by nucleophilic attack of the 3'-hydroxyl group at the 3' terminus of the primer on the α phosphate of the Mn-dNTP chelate 9. ³²P of labeling reagent 8 may well have been eliminated from the photoaffinity labeling reagent as pyrophosphate before the photo-reaction in our experiments. We found that the photolabeling of HIV-1 reverse transcriptase with cold TDSddUTP (7) and poly(A)-[³²P]oligo(dT)₁₆ as the templateprimer in the presence of Mn²⁺ gave a radioactive polypeptide at about 80 kDa (data not shown). From this preliminary data, it seems likely that the photolabile primer analog was formed by addition of TDSddUMP onto [32P]oligo(dT)16 and then could covalently bind to the enzyme molecule. As shown in Figure 3, generation of the radiolabeled product was strongly inhibited by addition of dTTP, indicating that TDSddUTP (8) could bind to the dTTP binding site of HIV-1 reverse transcriptase.

We have already reported in a previous study that the *K*i value of StddUTP for DNA polymerase γ was 10 times smaller than that for HIV-1 reverse transcriptase when poly(A)-oligo(dT) was used as the template-primer ¹². In the present study, we suggest that our newly synthesized labeling reagents **7** and **8** should be useful tools for elucidation of the active site, and particularly the dTTP binding site, of eukaryotic DNA polymerase γ as well as HIV-1 reverse transcriptase.

ACKNOWLEDGEMENTS

We thank Miss Hiroko Ishido, Miss Fumiko Taki and Prof. Shiro Ikegami, Faculty of Pharmaceutical Sciences, Teikyo University, for their ¹H-NMR and mass spectrometer results and helpful advice.

REFERENCES

- Part XXXIII of this series: Kawaguchi, T.; Sakairi, H.; Kimura, S.; Yamaguchi, T.; Saneyoshi, M. Chem. Pharm. Bull. 1995, 43, 501-504.
- (2) Mitsuya, H.; Yarchoan, R.; Broder, S. Science 1990, 249, 1533-1544.
- (3) Furman, P. A.; Fyfe, J. A.; St. Clair, M. H.; Weinhold, K.; Rideout, J. L.; Freeman, G. A.; Lehrman, S. N.; Bolognesi, D. P.; Broder, S.; Mitsuya, H.; Barry, D. W. Proc. Natl. Acad. Sci. USA 1986, 83, 8333–8337.
- (4) St. Clair, M. H.; Richards, C. A.; Spector, T.; Weinhold, K. J.; Miller, W. H.; Langlois, A. J.; Furman, P. A. Antimicrob. Agents Chemother. 1987, 31, 1972-1977.
- (5) DeClercq, E. Nucleosides Nucleotides **1991**, 10, 167–180.
- (6) Krayevsky, A. A.; Watanabe, K. A. Modified nucleosides as anti-AIDS drug: current status and perspective. **1993**, Bioinform, Moscow.
- (7) Matthes, E.; Lehmann, Ch.; Scholz, D.; von Janta-Lipinski, M.; Gaertner, K.; Rosenthal, H. A.; Langen, P. Biochem. Biophys. Res. Commun. 1987, 148, 78–85.
- (8) Chen, M. S.; Oshana, S. C. Biochem. Pharmacol. 1987, 36, 4361-4362.
- (9) Wright, G. E.; Brown, N. C. Pharmac. Ther. 1990, 47, 447-497.
- (10) Kohlstaedt, L. A.; Wang, J.; Friedman, J. M.; Rice, P. A.; Steitz, T. A. Science 1992, 256, 1783–1790.
- (11) Jacobo-Molina, A.; Ding, J.; Nanni, R. G.; Clark, A. D. Jr.; Lu, X.; Tantillo, C.;
 Williams, R. L.; Kamer, G.; Ferris, A. L.; Clark, P.; Hizi, A.; Hughes, S. H.;
 Arnold, E. Proc. Natl. Acad. Sci. USA 1993, 90, 6320–6324.
- (12) Yamaguchi, T.; Izuta, S.; Suzuki, M.; Yoshida, S.; Matsukage, A.; Saneyoshi, M. Nucleosides Nucleotides 1994, 13, 1247-1258.
- (13) Brunner, J.; Senn, H.; Richards, F. M. J. Biol. Chem. 1980, 255, 3313-3318.
- (14) Hakanaka, Y.; Yoshida, E.; Nakayama, H.; Abe, T.; Satake, M.; Kanaoka, Y. *FEBS Lett.* **1990**, *260*, 27–30.
- (15) Nassal, M. Liebigs Ann. Chem. 1983, 1510-1523.
- (16) Laemmli, U. K. Nature (London) 1970, 227, 680-685.
- (17) Bigge, Christopher F.; Kalaritis, Panos; Deck, Joanne R.; Mertes, Mathias. P. J. Am. Chem. Soc. 1980, 102, 2033–2038.
- (18) Yamaguchi, T.; Saneyoshi, M. Nucleosides Nucleotides 1992, 11, 373-382.
- (19) Bergstrom, D. E.; Ruth, J. L. J. Carbohydr. Nucleosides Nucleotides 1977, 4, 257–269.
- (20) Yoshikawa, M.; Kato, T.; Takenishi, T. Bull. Chem. Soc. Jpn. 1969, 42, 3505–3508.
- (21) Maeda, M.; Patel, A. D.; Hampton, A. Nucleic Acids Res. 1977, 4, 2843-2853.
- (22) Glynn, I. M.; Chappell, J. B. Biochem. J. 1964, 90, 147-149.
- (23) Wu, J. C.; Warren, T. C.; Adams, J.; Proudfoot, J.; Skiles, J.; Raghavan, P.; Perry, C.; Potocki, I.; Farina, P. R.; Grob, P. M. *Biochemistry* 1991, 30, 2022-2026.

- (24) Cohen, K. A.; Hopkins, J.; Ingraham, R. H.; Pargellis, C.; Wu, J. C.; Palladino, D. E. H.; Kinkade, P.; Warren, T. C.; Rogers, S.; Adams, J.; Farina, P. R.; Grob, P. M. J. Biol. Chem. 1991, 266, 14670-14674.
- (25) Evans, R. K.; Haley, B. E. Biochemistry 1987, 26, 269-276.
- (26) Izuta, S.; Saneyoshi, M. Biochem. Biophys. Res. Commun. 1989, 161, 514–519.